非酒精性脂肪性肝病——全球公共卫生视角
全球肥胖和2型糖尿病流行使非酒精性脂肪性肝病(NAFLD)患病率成比例增加,其亚型非酒精性脂肪性肝炎(NASH)可进展为肝硬化、肝细胞癌、需肝移植和死亡。NAFLD还伴随慢性肾病、心血管疾病和睡眠呼吸暂停等肝外表现,造成巨大经济负担和健康相关生活质量下降。尽管肝纤维化F3或F4患者肝相关死亡风险增加,但主要死因是心血管疾病。
要点
- 全球肥胖和2型糖尿病流行使NAFLD患病率成比例增加。
- NASH可进展为肝硬化、肝细胞癌、肝移植和死亡。
- NAFLD肝纤维化F3或F4患者肝相关死亡风险增加,但主要死因是心血管疾病。
核心结论
- 鉴于NAFLD和NASH全球负担迅速增长,必须继续努力寻找准确的無创诊断和预后生物标志物,开发针对晚期NASH个体的有效治疗以及针对NAFLD和进展性肝病高危个体的预防方法。
研究设计与样本
- 本文为全球公共卫生视角的综述,检索范围原文未报告。
主要发现
- NAFLD与慢性肾病、心血管疾病和睡眠呼吸暂停等肝外表现相关。
- NAFLD和NASH带来巨大经济负担并造成健康相关生活质量下降。
- NAFLD和肝纤维化F3或F4患者肝相关死亡风险增加,但主要死因是心血管疾病。
关键数值与推荐
- 原文未报告具体诊断标准或数值阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea. NAFLD and NASH carry a large economic burden and create poor health-related quality of life. Despite this important burden, we are only beginning to understand its mechanisms of pathogenesis and the contribution of environmental and genetic factors to the risk of developing a progressive course of disease. Research is underway to identify appropriate non-invasive diagnostic methods and effective treatments. Although the risk of liver-related mortality is increased in patients with NAFLD and liver fibrosis stages F3 or F4, the leading cause of death is cardiovascular disease. Given the rapidly growing global burden of NAFLD and NASH, efforts must continue to find accurate non-invasive diagnostic and prognostic biomarkers, to develop effective treatments for individuals with advanced NASH and prevention methods for individuals at high risk of NAFLD and progressive liver disease.
引用
- Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018. PMID: 30414863. doi:10.1016/j.jhep.2018.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。